Genesis Pharmaceuticals Announces Cooperation Agreement - 500 Beiträge pro Seite

[V51]

GNY


us 0,30 $ = 0,20 e gestern. noch billig also



Genesis Pharmaceuticals Announces Cooperation Agreement with T
e Institute of Microbiology, Chinese Academy of Scien
B: Genesis Pharmaceuticals Announces Cooperation Agreement with The Institute of
Microbiology, Chinese Academy of Sciences ( PrimeNewswire )

LAIYANG, China, Nov 21, 2007 (PrimeNewswire via COMTEX) --
Genesis Pharmaceuticals Enterprises, Inc. (OTCBB:GTEC) ("Genesis" or the
"Company"), a U.S. pharmaceutical company with its principal operations in
the People's Republic of China, today announced that it signed a cooperation
agreement with The Institute of Microbiology, Chinese Academy of Sciences
(IMCAS), a research institution in China that performs a wide spectrum of
basic and applied research in the field of microbiology.

According to the cooperation agreement, Genesis and IMCAS will build a
"Genesis Pharmaceuticals Industrialization Model" to do joint research with
the goal of commercializing pharmaceutical discoveries. This
Industrialization Model is IMCAS' first cooperative arrangement with a
pharmaceuticals manufacturing company.

Genesis will fund the Industrialization Model's daily operations and
research and development activities. Once new drugs have completed a first
stage of experiments in the Industrialization Model, they will be delivered
to Genesis's factory for further testing to determine the viability of
commercial wide-scale production. Genesis' research and development staff
will work with researchers from IMCAS to resolve issues that arise during the
process of designing the manufacturing process for new drugs. Genesis will
have the first right to purchase patents for any products developed by the
Industrialization Model and IMCAS.

"We are very pleased that IMCAS chose Genesis to be its partner in the
commercialization of new drug discoveries," said Mr. Cao Wubo, Chairman and
CEO of Genesis Pharmaceuticals Enterprises, Inc. "Because IMCAS is the
national leading research institution in the field of microbiology, we
believe collaboration will bring valuable research and develop expertise to
Genesis and strengthen our own R&D force. This will extend our company's use
of cutting edge technologies as well as solidify our leading position in the
Chinese pharmaceutical market."

About IMCAS

The Institute of Microbiology, Chinese Academy of Sciences (IMCAS) was
founded on December 3, 1958. It is a national comprehensive research
institution that performs a wide spectrum of basic and applied research in
the field of microbiology. IMCAS hosts 300 faculty and staff, including 5 CAS
academicians. Currently, it has three key laboratories: State Key Laboratory
of Microbial Resources, State Key Laboratory of Plant Genomics, and CAS Key
Laboratory of Systematic Mycology and Lichenology as well as nine research
centers which carry out studies on microbial resources, microbial genomics,
agricultural biotechnology, bio-energy and industrial biotechnology,
environmental biotechnology, extremophiles, microbial metabolic engineering,
molecular virology, and molecular immunology, As the national leading
research and development organization in China, IMCAS successfully developed
SARS vaccine.

As the national leading research institution in the field of microbiology,
the IMCAS is committed to the advancement of science and technology. During
the last 40 years, it has attained a number of developmental achievements in
molecular evolution, pathogenicity, and cross-species propagation, as well as
antiviral fields which can be the initial force for industrialization process.

About Genesis Pharmaceuticals Enterprises

Genesis Pharmaceuticals Enterprises, Inc. is a U.S. public company engaged
in the research, development, production, marketing and sales of
pharmaceutical products in the People's Republic of China. Its operations are
located in Northeast China in an Economic Development Zone in Laiyang City,
Shandong province. Genesis is a major pharmaceutical company in China
producing tablets, capsules, and granules for both western and Chinese
herbal-based medical drugs. The Company maintains a representative office in
the U.S. For more information, refer to http://www.Genesis-China.net

Safe Harbor Statement

Certain statements set forth in this press release constitute
"forward-looking statements." Such statements are not guarantees of future
performance and are subject to risks and uncertainties that could cause the
Company's actual results and financial position to differ materially from
those included within the forward-looking statements. Forward-looking
statements involve risks and uncertainties, including those relating to the
Company's ability to introduce, manufacture and distribute new drugs. Actual
results may differ materially from predicted results, and reported results
should not be considered as an indication of future performance. The
potential risks and uncertainties include, among others, the Company's
ability to obtain raw materials needed in manufacturing, the continuing
employment of key employees, the failure risks inherent in testing any new
drug, the possibility that regulatory approvals may be delayed or become
unavailable, patent or licensing concerns that may include litigation, direct
competition from other manufacturers and product obsolescence. More
information about the potential factors that could affect the Company's
business and financial results is included in the Company's filings,
available via the United States Securities and Exchange Commission.

This news release was distributed by PrimeNewswire, www.primenewswire.com

SOURCE: Genesis Pharmaceuticals Enterprises, Inc.
Genesis Pharmaceuticals Enterprises, Inc.
Ms. Elsa Sung, CFO
877-895-3650, Ext. 701
[e-mail]
CCG Elite Investor Relations, Inc.
Mr. Crocker Coulson, President
[phone] (New York)
[e-mail]
(C) Copyright 2007 PrimeNewswire, Inc. All rights reserved.
*** end of story ***

[V51]

0,50 wieder drin bis Freitag